Table 1.
Site of involvement* | Sarcoidosis (n=39) | Hodgkin’s Lymphoma (n=37) | p-value |
---|---|---|---|
1 | 9 (23.1%) | 17 (45.9%) | 0.036 |
2 | 22 (56.4%) | 26 (70.3%) | 0.211 |
3 | 10 (25.6%) | 30 (81.1%) | 0.000 |
4 | 38 (97.4%) | 33 (89.2%) | 0.147 |
5 | 27 (69.2%) | 24 (64.9%) | 0.686 |
6 | 21 (53.8%) | 21 (56.8%) | 0.799 |
7 | 30 (76.9%) | 27 (73.0%) | 0.691 |
8 | 12 (30.8%) | 15 (40.5%) | 0.374 |
9 | 7 (17.9%) | 4 (10.8%) | 0.377 |
10** 10R 10L 10B |
35 (89.7%) 2 (5.1%) 1 (2.5%) 32 (82.0%) |
23 (62.2%) 7 (18.9%) 7 (18.9%) 9 (24.3%) |
0.005 0.082 0.027 0.000 |
Axillary | 5 (12.8%) | 8 (21.6%) | 0.370 |
Peridiaphragmatic | 1 (2.5%) | 2 (5.4%) | 0.610 |
Internal mammary | 0 (0.0%) | 11 (29.7%) | 0.000 |
Retrocrural | 0 (0.0%) | 5 (13.5%) | 0.024 |
10R (Right unilateral hilar), 10L (Left unilateral hilar), 10B (Bilateral hilar);
according to the International Association for the Study of Lung Cancer (IASLC) lymph node map [6].